Rallybio Pivots as Antibody for Rare Bleeding Disorder Flunks Dosing Trial

The company is dropping its former lead molecule in favor of another antibody, RLYB116, which is being developed for a variety of rare autoimmune disorders.

Rallybio is discontinuing the development of its former lead molecule in a rare autoimmune bleeding disorder. The biotech’s decision, announced Tuesday, comes after a disappointing pharmacokinetic readout from a Phase II trial.

RLYB212 is a human monoclonal antibody the company was developing to treat fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare bleeding disorder in which a mother’s immune system attacks a fetus or newborn’s platelets.

Rallybio’s data showed that the antibody was not reaching predicted target concentrations (6–10 ng/mL) or the minimum target concentration required for efficacy (3 ng/mL).

“Given that the results significantly deviated from the predicted range and the absence of empiric data to further inform dose adjustment, the risk/benefit no longer supports continued dosing, and we will discontinue RLYB212 development,” CEO Stephen Uden said in the statement.

The Connecticut-based company will continue development on another molecule, RLYB116, an antibody fusion protein that inhibits a protein in the complement pathway, a part of the body’s innate immune system. Rallybio is pushing RLYB116, currently in Phase I trials, for diseases resulting in rare disorders of the complement pathway, including paroxysmal nocturnal hemoglobinuria (PNH), antiphospholipid syndrome (APS) and generalized myasthenia gravis (gMG).

The discontinuation is a fork in the road for Rallybio. The company launched in 2018, backed by multiple funding rounds totaling nearly $250 million, to investigate new treatments for rare and ultrarare conditions. In addition to RLYB212’s discontinuation, molecules like RLYB211, another FNAIT-targeting molecule it had previously touted, no longer appears in the company’s published pipeline.

Other than RLYB116, the company’s pipeline is preclinical and includes a small molecule for hypophosphatasia, a rare and inherited metabolic bone disorder, discovered in a research partnership with Recursion, and an antibody for iron overload and anemias.

Dan Samorodnitsk has a decade of experience covering biotech, genetics and medicine at BioSpace, Drug Discovery News and Massive Science. His writing has appeared in outlets such as Quanta, STAT, GROW and many others. You can follow him on LinkedIn.
MORE ON THIS TOPIC